Adaptive immunity in HBV infection

Antonio Bertoletti; Carlo Ferrari

doi:10.1016/j.jhep.2016.01.026

Adaptive immunity in HBV infection

J Hepatol. 2016 Apr;64(1 Suppl):S71-S83. doi: 10.1016/j.jhep.2016.01.026.

Authors

Antonio Bertoletti¹, Carlo Ferrari²

Affiliations

¹ Emerging Infectious Diseases (EID) Program, Duke-NUS Medical School, Singapore; Viral Hepatitis Laboratory, Singapore Institute for Clinical Sciences, Agency of Science Technology and Research (A*STAR), Singapore. Electronic address: [email protected].
² Divisione Malattie Infettive, Ospdale Maggiore Parma, Parma, Italy.

PMID: 27084039
DOI: 10.1016/j.jhep.2016.01.026

Abstract

During hepatitis B virus (HBV) infection, the presence of HBV-specific antibody producing B cells and functional HBV-specific T cells (with helper or cytotoxic effects) ultimately determines HBV infection outcome. In this review, in addition to summarizing the present state of knowledge of HBV-adaptive immunity, we will highlight controversies and uncertainties concerning the HBV-specific B and T lymphocyte response, and propose future directions for research aimed at the generation of more efficient immunotherapeutic strategies.

Keywords: Antiviral immunity; B lymphocytes; Immunodominance; T cell exhaustion; T lymphocytes.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Adaptive Immunity*
Antiviral Agents / therapeutic use*
Hepatitis B Core Antigens / immunology*
Hepatitis B Surface Antigens / immunology*
Hepatitis B virus / immunology*
Hepatitis B, Chronic / drug therapy
Hepatitis B, Chronic / immunology
Hepatitis B, Chronic / virology*
Humans
T-Lymphocytes / immunology*

Substances

Antiviral Agents
Hepatitis B Core Antigens
Hepatitis B Surface Antigens